Celltrion is likely to have posted record-breaking results in 2025, marking the first time in its history that annual revenue and operating profit surpassed $3 billion and $750 million, respectively.
The South Korean biopharmaceutical company announced on Wednesday that it expects consolidated fourth-quarter revenue of 1.28 trillion won ($960 million) and operating profit of 472.2 billion won, representing year-over-year increases of 20.7% and 140.4%, respectively.
If confirmed, the figures would mark the company’s highest-ever quarterly revenue and operating profit achieved simultaneously, with an operating margin projected at 36.8%.
On a full-year basis, Celltrion forecasts 2025 revenue of 4.12 trillion won ($3.1 billion), up 15.7% from a year earlier, while operating profit is expected to surge 136.9% to 1.166 trillion won ($880 million). The results would represent a historic milestone for the company.
The strong performance reflects steady growth in legacy products alongside the rapid global expansion of newly launched, high-margin biosimilars.
In the fourth quarter, new products, including Remsima SC, marketed as Zymfentra in the US, Yuflyma, Vegzelma and Steqeyma, are all expected to post double-digit growth rates.
These products are projected to account for more than 60% of quarterly sales, underscoring their growing contribution to overall earnings.
Some new product launches were delayed due to patent settlements and supply-related factors, limiting their impact on full-year results. However, the company expects these products to expand market share from next year, driving stronger growth momentum and improved profitability from 2026 onward.
Profitability has also benefited from the full normalization of operations following Celltrion’s merger with Celltrion Healthcare in December 2023. The impact of high-cost inventory clearance and development cost amortization has largely subsided, while ongoing improvements in production yields are expected to further support margin expansion.
Looking ahead, Celltrion said it will focus on profit-driven growth by reducing exposure to low-margin products and maximizing returns from high-margin offerings.
With a portfolio of 11 biosimilar products secured across major global markets, the company plans to accelerate country-by-country launches centered on newer products.
The expanded lineup also enables bundled bidding strategies, which are expected to further strengthen its competitive position.
Celltrion has also outlined a mid- to long-term strategy to expand its contract development and manufacturing organization (CDMO) business, linked to the establishment of production facilities in the US.
Capital investment and infrastructure development will be handled by Celltrion and its US subsidiaries, while global sales and project management will be led by Celltrion Biosolutions, a dedicated CDMO unit established last year.
The company also plans to secure additional drug product (DP) and drug substance (DS) manufacturing facilities in Korea.
A Celltrion official said the company has released preliminary earnings ahead of official disclosures since the first quarter of this year to enhance transparency and timeliness for investors.
“This quarter marks the first time we have announced performance forecasts before the end of the reporting period to further improve predictability,” the official said, adding that conservative assumptions were applied to account for market volatility.
“From 2026, we will focus on sustainable, profit-oriented growth built around our high-margin product portfolio.”
